Analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) and Child-Pugh (CP)-B liver function treated with regorafenib in routine clinical practice in the observational REFINE study

• Published in: Journal of clinical oncology Vol. 42; no. 3_suppl; p. 452
• Main Authors: Merle, Philippe, Finn, Richard S., Kudo, Masatoshi, Klümpen, Heinz-Josef, Lim, Ho Yeong, Pinter, Matthias, Babajanyan, Svetlana, Khan, Javeed, Awan, Maria, Özgürdal, Kirhan, Qin, Shukui
• Format: Journal Article
• Language: English
• Published: American Society of Clinical Oncology 20.01.2024

452Background: Pts with HCC and compromised liver function are typically excluded from clinical trials. The REFINE real-world study (NCT03289273) assessed a more varied pt population treated with regorafenib than the phase 3 RESORCE trial.1 Median overall survival (OS) in REFINE was 13.2 months and...